WORLD PEPTIDEFOUNDATION

Peptide directory

Find a peptide

Public profiles inside a larger governed registry

Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.

Browse the Master RegistryExplore research atlasesFind studies worldwide

The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.

Published profiles

Search profiles and sources

Compare peptides side by side →
Refine by category
Category

1 peptide records

  • GLP-1 receptor agonist

    Semaglutide

    Peptide analog

    Substantial

    Matched on: name

    Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1) engineered for resistance to DPP-4 degradation and prolonged albumin binding. It selectively activates the GLP-1 receptor. In humans, its pharmacologic effects include glucose-dependent stimulation of insulin secretion, reduced glucagon secretion, delayed gastric emptying, reduced calorie intake, and lower body weight. Clinical effects and approved uses depend on the formulation, indication, population, and regulatory jurisdiction; this archive separates those contexts rather than treating semaglutide as a single undifferentiated claim.

    Evidence and record details

    Evidence integrity map

    Human 22Preclinical 1Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    25 open research questions
    Evidence review date
    Documented human review recorded Sep 22, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

    View evidence profile for Semaglutide
How the public directory relates to the 500-record Master Registry

master registry transparency

500 master records, with governance status shown explicitly

WPF-MASTER-REGISTRY-TRANSPARENCY-1.0
501
Master records
467
Governed records
34
Review-deferred
458
Peptide acquisition eligible
9
Governed comparators

The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the source acquisition cohort. Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.

Explore the full Master Registry →
What the profile status labels mean

Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.

Recently updated public records

When each public profile record was last changed — not clinical or scientific activity.

Peptide Directory — World Peptide Foundation